E
Edward E. Kadel
Researcher at Genentech
Publications - 39
Citations - 6404
Edward E. Kadel is an academic researcher from Genentech. The author has contributed to research in topics: Atezolizumab & PD-L1. The author has an hindex of 12, co-authored 34 publications receiving 3852 citations.
Papers
More filters
Journal ArticleDOI
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Sanjeev Mariathasan,Shannon J. Turley,Dorothee Nickles,Alessandra Castiglioni,Kobe C. Yuen,Yulei Wang,Edward E. Kadel,Hartmut Koeppen,Jillian L. Astarita,Rafael Cubas,Suchit Jhunjhunwala,Romain Banchereau,Yagai Yang,Yinghui Guan,Cecile Chalouni,James Ziai,Yasin Senbabaoglu,Stephen Santoro,Daniel Sheinson,Jeffrey Hung,Jennifer M. Giltnane,Andrew A. Pierce,Kathryn Mesh,Steve Lianoglou,Johannes Riegler,Richard A.D. Carano,Pontus Eriksson,Mattias Höglund,Loan Somarriba,Daniel L. Halligan,Michiel S. van der Heijden,Yohann Loriot,Jonathan E. Rosenberg,Lawrence Fong,Ira Mellman,Daniel S. Chen,Marjorie C. Green,Christina Louise Derleth,Gregg Fine,Priti S. Hegde,Richard Bourgon,Thomas Powles +41 more
TL;DR: Tumours from a large cohort of patients with metastatic urothelial cancer who were treated with an anti-PD-L1 agent were examined and major determinants of clinical outcome were identified and suggested that TGFβ shapes the tumour microenvironment to restrain anti-tumour immunity by restricting T-cell infiltration.
Journal ArticleDOI
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Arjun Vasant Balar,Matthew D. Galsky,Jonathan E. Rosenberg,Thomas Powles,Daniel P. Petrylak,Joaquim Bellmunt,Yohann Loriot,Andrea Necchi,Jean H. Hoffman-Censits,Jose Luis Perez-Gracia,Nancy A. Dawson,Michiel S. van der Heijden,Robert Dreicer,Sandy Srinivas,Margitta Retz,Richard W. Joseph,Alexandra Drakaki,Ulka N. Vaishampayan,Srikala S. Sridhar,David I. Quinn,Ignacio Duran,David R. Shaffer,Bernhard J. Eigl,Petros Grivas,Evan Y. Yu,S. Li,Edward E. Kadel,Zachary Boyd,Richard Bourgon,Priti S. Hegde,Sanjeev Mariathasan,Ann Christine Thastrom,Oyewale O. Abidoye,Gregg Fine,Dean F. Bajorin +34 more
TL;DR: Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer.
Journal ArticleDOI
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Thomas Powles,Ignacio Duran,Michiel S. van der Heijden,Yohann Loriot,Nicholas J. Vogelzang,Ugo De Giorgi,Stéphane Oudard,Margitta Retz,Daniel Castellano,Aristotelis Bamias,Aude Flechon,Gwenaelle Gravis,Syed A. Hussain,Toshimi Takano,Ning Leng,Edward E. Kadel,Romain Banchereau,Priti S. Hegde,Sanjeev Mariathasan,Na Cui,Xiaodong Shen,Christina Louise Derleth,Marjorie C. Green,Alain Ravaud +23 more
TL;DR: Atezolizumab was not associated with significantly longer overall survival than chemotherapy in patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1, thus precluding further formal statistical analysis.
Journal ArticleDOI
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Kobe C. Yuen,Li-Fen Liu,Vinita Gupta,Shravan Madireddi,Shilpa Keerthivasan,Congfen Li,Deepali Rishipathak,Patrick Williams,Edward E. Kadel,Hartmut Koeppen,Ying-Jiun Chen,Zora Modrusan,Jane L. Grogan,Romain Banchereau,Ning Leng,A. Thåström,X. Shen,Kenji Hashimoto,Darren Tayama,Michiel S. van der Heijden,Jonathan E. Rosenberg,David F. McDermott,Thomas Powles,Priti S. Hegde,Mahrukh Huseni,Sanjeev Mariathasan +25 more
TL;DR: Increased baseline peripheral and tumor IL-8 levels were associated with worse clinical outcomes in patients with metastatic urothelial carcinoma and metastatic renal cell carcinoma treated with anti-PD-L1 therapy.
Journal ArticleDOI
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
Marcin Kowanetz,Wei Zou,Scott N. Gettinger,Hartmut Koeppen,Mark M. Kockx,Peter Schmid,Edward E. Kadel,Ignacio I. Wistuba,Jamie E. Chaft,Naiyer A. Rizvi,David R. Spigel,Alexander I. Spira,Fred R. Hirsch,Victor Cohen,Dustin Smith,Zach Boyd,Natasha Miley,Susan Flynn,Vincent Leveque,David S. Shames,Marcus Ballinger,Simonetta Mocci,Geetha Shankar,Roel Funke,Garret Hampton,Alan Sandler,Lukas C. Amler,Ira Mellman,Daniel S. Chen,Priti S. Hegde +29 more
TL;DR: PD-L1 expression on TC or IC can independently attenuate anticancer immunity and emphasizes the functional importance of IC in regulating the antitumor T cell response.